US: CHJTF - CSPC Pharmaceutical Group Ltd

半年間の収益性: +20.37%
配当利回り: +4.95%

プロモーションスケジュール CSPC Pharmaceutical Group Ltd


会社について CSPC Pharmaceutical Group Ltd

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments.

さらに詳しく
It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

ISIN HK1093012172
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета cny
Див.доход ао 5.75
Дивиденд ао 0.0385
Сайт https://www.cspc.com.hk
Цена ао 0.54
1日あたりの価格変動: +20.37% (0.54)
週ごとの価格変動: +20.37% (0.54)
月ごとの料金変更: +20.37% (0.54)
3ヶ月間の価格変動: 0% (0.65)
半年間の価格変動: +20.37% (0.54)
年間の価格変動: -72.22% (2.34)
3年間の価格推移: 0% (0.65)
5年間の価格推移: 0% (0.65)
10年間の価格推移: 0% (0.65)
年初からの価格変動: +10.17% (0.59)

過小評価

名前 意味 学年
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
合計: 2.5

効率

名前 意味 学年
ROA, % 0 0
ROE, % 0 0
合計: 0

配当金

名前 意味 学年
Div yield, % 4.95 10
DSI 0.9286 9.29
合計: 6.6

義務

名前 意味 学年
Debt/EBITDA 0 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % 975.65 10
収益性 Ebitda, % 1040.38 10
収益性 EPS, % 54.59 7
合計: 9.4

スーパーバイザー 役職 支払い 生年
Mr. Dongchen Cai Executive Chairman 1954 (71 年)
Mr. Cuilong Zhang Vice-Chairman & CEO 1969 (56 年)
Mr. Chunlei Li Executive Director & Chief Scientist 1976 (49 年)
Mr. Weidong Pan Executive Director 1969 (56 年)
Mr. Huaiyu Wang Executive Director 1963 (62 年)
Mr. Zhenguo Wang Executive Director 1970 (55 年)
Dr. Hao Jiang Executive Director 1984 (41 年)
Mr. Xin Cai Group Executive President, President of the Group's Marketing Strategy Division & Executive Director 1991 (34 年)
Dr. Bing Yao Executive Director 1977 (48 年)
Dr. Yongjun Liu Executive president & President of Global Research and Development

住所: China, Shijiazhuang, No. 226 Huanghe Street - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.cspc.com.hk